David A Sallman Selected Research

eprenetapopt

10/2021	Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
10/2021	Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).
1/2020	To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David A Sallman Research Topics

Disease

16	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 12/2016
14	Neoplasms (Cancer) 01/2022 - 11/2007
11	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2021 - 01/2014
4	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2022 - 01/2020
3	Primary Myelofibrosis (Myelosclerosis) 01/2019 - 12/2017
2	Anemia 01/2022 - 03/2019
2	Febrile Neutropenia 10/2021 - 10/2021
2	Leukocytosis (Pleocytosis) 10/2021 - 12/2017
2	Leukopenia 10/2021 - 03/2019
2	Hematologic Neoplasms (Hematological Malignancy) 03/2019 - 01/2017
2	Splenomegaly 03/2018 - 12/2017
1	Inflammation (Inflammations) 01/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022
1	Bites and Stings (Sting) 01/2022
1	Leukemia 11/2021
1	Neutropenia 10/2021
1	Pathologic Complete Response 01/2020
1	Thrombocytosis (Thrombocythemia) 03/2019
1	Disease Progression 01/2017
1	Disease Susceptibility (Diathesis) 10/2015
1	Aplastic Anemia (Anemia, Hypoplastic) 01/2014
1	Autoimmune Diseases (Autoimmune Disease) 04/2009
1	Prostatic Neoplasms (Prostate Cancer) 11/2007

Drug/Important Bio-Agent (IBA)

4	Azacitidine (5 Azacytidine)FDA Link 10/2021 - 01/2020
3	Lenalidomide (CC 5013)FDA Link 01/2022 - 01/2014
3	InflammasomesIBA 01/2022 - 12/2016
3	Biological ProductsIBA 01/2022 - 01/2014
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2009
3	ruxolitinibIBA 11/2021 - 12/2017
3	eprenetapoptIBA 10/2021 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2018
2	ClusterinIBA 06/2010 - 11/2007
2	Docetaxel (Taxotere)FDA Link 06/2010 - 11/2007
1	axicabtagene ciloleucelIBA 01/2022
1	venetoclaxIBA 01/2022
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2022
1	RNA Splicing FactorsIBA 01/2022
1	Chimeric Antigen ReceptorsIBA 01/2022
1	GATA Transcription FactorsIBA 01/2022
1	Biological FactorsIBA 01/2022
1	Carrier Proteins (Binding Protein)IBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	Erythropoietin FDA Link 01/2022
1	Peptide Hydrolases (Proteases)FDA Link 01/2022
1	Pharmaceutical PreparationsIBA 10/2021
1	MDS 11IBA 10/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	magrolimabIBA 12/2020
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2020
1	lenzilumabIBA 01/2020
1	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2020
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2020
1	selinexorIBA 01/2020
1	Oncogene Proteins (Oncogene Protein)IBA 01/2019
1	glasdegibIBA 01/2019
1	PrionsIBA 09/2018
1	Glucose (Dextrose)FDA LinkGeneric 09/2018
1	Thalidomide (Thalomid)FDA Link 12/2017
1	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2017
1	API 2IBA 06/2010
1	ResveratrolIBA 11/2007

Therapy/Procedure

18	Therapeutics 01/2022 - 10/2015
3	Drug Therapy (Chemotherapy) 01/2022 - 01/2017
1	Drug Tapering 10/2021
1	Precision Medicine 09/2021
1	Induction Chemotherapy 01/2020
1	Transplantation 01/2019
1	Salvage Therapy 03/2018
1	Immunotherapy 01/2017